Atara Biotherapeutics Q3 revenue beats estimates as costs decline

Overview

• US T-cell immunotherapy developer's Q3 revenue fell yr/yr but beat analyst expectations

• Company narrowed Q3 net loss compared to prior year

• Operating expenses declined sharply, reflecting ongoing cost-reduction efforts

Outlook

• Atara expects operating expenses to decline significantly year-over-year in 2026

• Company anticipates cash and investments will fund operations into mid-2027

• FDA sets March 31, 2027 target action date for tab-cel BLA

Result Drivers

• REVENUE DECLINE - Co said lower Q3 revenue was primarily due to a one-time sale of clinical inventory in the prior year

• COST REDUCTION - Co attributed significant decline in operating expenses to cost-reduction initiatives implemented in 2025 and early 2026

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Atara Biotherapeutics, Inc. is $13.00, about 58.9% above its November 9 closing price of $8.18

• The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 363 three months ago

Reuters Recommended Reads

• Nov 9 - Immunovant Q2 net loss narrows on lower R&D costs

• Nov 9 - Editas Medicine Q3 net loss narrows

• Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)